Breast Cancer in the Post-Genomic Era

Breast cancer is the most common tumor in women. It is the second leading cause of cancer deaths worldwide. In this book, international authorities offer a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma.

Potential Contributors and Temptative Titles Section I: The biology of the mammary gland: Jose Russo, Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA Title: Mammary gland development Gilbert H. Smith Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, 20892, Maryland Title: Mammary gland, stem cells and breast cancer Section II: The genetic background of breast cancer Barbara L. Weber, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, 514 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA Title: The genetic of breast cancer: application in clinical practice Ashok R. Venkitaraman, University of Cambridge, CR UK Department of Oncology and The Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge, CB2 2XZ, U.K Title: Cancerogenesis associated with mutations in BRCA genes Section III: Epigenetic and molecular alterations in breast cancer Nancy E. Davidson, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, MD 21231 Title: DNA methylation in breast cancer Antonio Giordano, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, 1900 North 12th Street, Philadelphia, PA 19122, USA Title: Alterations of cell cycle regulatory genes in breast cancer David S. Salomon, Tumor Growth Factor Section, Mammary Biology & Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg 10, Rm. 5B39, Bethesda, Maryland 20892 Title: Role of the cripto (EGF-CFC) family in mammary gland development and neoplasia William J Gullick, Department of Biosciences, University of Kent at Canterbury, Canterbury, Kent CT2 7NJ Title: Type I growth factor receptors and their ligands in breast cancer: clinical significance and future prospects for treatment William J. Muller, Institute for Molecular Biology and Biotechnology, Department of Biology, McMaster University, Hamilton, Ontario, Canada L8S 4K1 Title: Transgenic mouse models of breast cancer as model to study oncogene mediated signal transduction Section IV: New tools for diagnosis and prognostic assessment in breast cancer Eric S. Lander, Whitehead Institute/MIT Center for Genome Research, One Kendall Square, Building 300, Cambridge, Massachusetts 02139, USA Title: Gene expression profiling in breast cancer: clinical applications Emanuel F. Petricoin III, Center for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Boulevard, MS 4E3, Manassas, VA 20110 Title: Proteomics in breast cancer Section V: Novel therapeutic approaches Erik P. Winer, Dana-Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA. Title: The endocrine therapy of breast cancer in the era of the aromatase inhibitors Nicola Normanno, Cell Biology and Preclinical Models Unit, INT-Fondazione Pascale, Naples, Italy Title: Signal transduction inhibitors for treatment and prevention of breast cancer Jose Baselga, Vall d'Hebron, University Hospital, Department of Medical Oncology, Pg Vall d'Hebron, 119-129, E-08035 Barcelona, Spain. Title: Monoclonal antibodies in breast cancer therapy: current status and future development Carlos L. Arteaga, Department of Cancer Biology, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232 USA Title: TGFbeta antagonists: a novel approach fro treatment of breast cancer? Francesco Perrone, Clinical Trials Unit, INT-Fondazione Pascale, Naples, Italy Integration of target based agents in current protocols of breast cancer therapy